Cosmo Pharmaceuticals N.V (C43) — Cash Flow-to-Debt Ratio
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2022, meaning its operating cash flow of €6.28 Million could theoretically repay 0% of its total liabilities (€296.03 Million) in one year. Check C43 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cosmo Pharmaceuticals N.V Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Cosmo Pharmaceuticals N.V across 10 annual periods. Also explore C43 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Cosmo Pharmaceuticals N.V (2016–2025)
Year-by-year debt coverage analysis for Cosmo Pharmaceuticals N.V. For market capitalisation and broader financial context, see market cap of Cosmo Pharmaceuticals N.V.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | €-12.48 Million | €123.46 Million | ▼ -108.8% |
| 2024 | 1.15x | €162.41 Million | €141.68 Million | ▲ +317.4% |
| 2023 | 0.27x | €33.62 Million | €122.42 Million | ▲ +144.5% |
| 2022 | 0.11x | €33.23 Million | €295.80 Million | ▲ +160.9% |
| 2021 | 0.04x | €12.61 Million | €292.88 Million | ▼ -35.0% |
| 2020 | 0.07x | €12.98 Million | €196.04 Million | ▲ +167.3% |
| 2019 | -0.10x | €-18.85 Million | €191.43 Million | ▼ -75.2% |
| 2018 | -0.06x | €-10.16 Million | €180.83 Million | ▲ +83.4% |
| 2017 | -0.34x | €-9.43 Million | €27.86 Million | ▼ -143.6% |
| 2016 | 0.78x | €21.69 Million | €27.92 Million | — |